Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASLAN Pharmaceuticals Pte Ltd

http://www.aslanpharma.com/

Latest From ASLAN Pharmaceuticals Pte Ltd

What Will Drive Korean Pharma's Next Decade Of Growth?

A recent event in South Korea heard one prominent investor advise South Korean pharma firms to sharply increase their new drug R&D and seek direct entry into global markets, rather than pursuing licensing deals for growth

South Korea Deals

ASLAN Falls As TreeTopp BTC Study Fails

ASLAN’s pivotal Phase II TreeTopp study of varlitinib in biliary tract cancer missed its co-primary endpoints of progression-free survival and overall response rate.

Cancer Clinical Trials

Asia Deal Watch: ASLAN, Bukwang Establish Immuno-Oncology JV In Singapore

The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.

Deals Business Strategies

Brighter News For Varlitinib As Results In Tough Cancer Type Encourage ASLAN

Following a major setback in another indication earlier this year, ASLAN’s lead asset is now seen as a potential new option for second-line use in biliary tract cancer following promising new data from a Chinese trial.

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register